| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.34▲ | 1.34▲ | 1.34▲ | 1.37▼ | 1.41▼ |
| MA10 | 1.34▼ | 1.33▲ | 1.33▲ | 1.40▼ | 1.43▼ |
| MA20 | 1.33▲ | 1.34▼ | 1.37▼ | 1.42▼ | 1.58▼ |
| MA50 | 1.35▼ | 1.39▼ | 1.40▼ | 1.46▼ | 1.92▼ |
| MA100 | 1.39▼ | 1.43▼ | 1.44▼ | 1.62▼ | 2.08▼ |
| MA200 | 1.43▼ | 1.46▼ | 1.49▼ | 1.96▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | 0.003▲ | 0.000▼ | -0.010▼ | -0.001▼ |
| RSI | 49.961▼ | 45.783▼ | 43.103▼ | 39.396▼ | 39.567▼ |
| STOCH | 39.583 | 42.824 | 29.375 | 15.714▼ | 30.974 |
| WILL %R | -50.000 | -55.556 | -80.000▼ | -88.889▼ | -80.948▼ |
| CCI | 23.514 | 64.734 | -24.927 | -130.050▼ | -136.714▼ |
|
Thursday, September 03, 2026 07:54 AM
ImmunityBio looks attractive due to ANKTIVA's FDA approval for BCG-unresponsive NMIBC and pipeline expansion potential. See why I rate IBRX stock a Buy.
|
|
Wednesday, August 26, 2026 10:49 AM
IBRX's aggressive R&D spend, weak financials, and emerging competition from TAR-200 and cretostimogene pose risks to future value realization. Click to read.
|
|
Thursday, August 20, 2026 07:30 AM
Track conference calls, annual meetings, summits, analyst days and other corporate events scheduled for Binah Capital Group Inc. Use the full market events calendar to scan activity across all tickers ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 03/09/26 | 1.39 | 1.3999 | 1.31 | 1.34 | 39,880 |
| 02/09/26 | 1.36 | 1.39 | 1.34 | 1.34 | 26,431 |
| 01/09/26 | 1.40 | 1.439 | 1.36 | 1.36 | 38,705 |
| 31/08/26 | 1.38 | 1.4162 | 1.38 | 1.405 | 14,225 |
| 28/08/26 | 1.41 | 1.42 | 1.38 | 1.395 | 16,555 |
| 27/08/26 | 1.45 | 1.46 | 1.4101 | 1.45 | 19,513 |
| 26/08/26 | 1.42 | 1.46 | 1.39 | 1.45 | 22,413 |
| 25/08/26 | 1.47 | 1.4799 | 1.41 | 1.445 | 17,453 |
| 24/08/26 | 1.45 | 1.46 | 1.435 | 1.45 | 24,991 |
| 21/08/26 | 1.38 | 1.4263 | 1.38 | 1.40 | 18,242 |
|
|
||||
|
|
||||
|
|